Polycystic ovary syndrome (PCOS), a hormonal disorder affecting 10% to 13% of women of reproductive age according to the World Health Organization, has long been misunderstood and underdiagnosed. It is estimated that more than two-thirds of those affected are unaware of their condition.
Why the Name Change Matters
The name of the condition has been partly blamed for the poor treatment many patients experience. Women's health experts argue that the term 'polycystic ovarian syndrome' is misleading and outdated, focusing on ovarian cysts which are not always present, while ignoring the broader metabolic aspects of the disorder.
Introducing PMOS
In a significant move, the condition has now been officially renamed to polyendocrine metabolic ovarian syndrome (PMOS). This change aims to reduce confusion and lead to better care by highlighting the endocrine and metabolic nature of the disorder.
Assistant science editor Donna Lu spoke to Nour Haydar about the implications of this renaming. The hope is that the new name will encourage more accurate diagnosis, reduce stigma, and improve treatment outcomes for millions of women worldwide.
Read more: ‘Unprecedented’ global effort gives new name to polycystic ovary syndrome – and new hope to millions of women.
